Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Douglas Ingram named president of Allergan

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Takeda reorganizes top leadership, corporate structure

Takeda has outlined plans to reorganize the company under a new leadership group.

Donald R. Joseph named chief legal officer at KaloBios

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

R&D cutbacks loom at Millennium's Cambridge ops

The new president at Millennium Pharmaceuticals has been trying to maintain a careful balancing act in recent weeks, trying to reassure staffers about Takeda's commitment to the oncology subsidiary while making it clear that cuts are coming.

UPDATED: Merck's new R&D chief Perlmutter begins major shakeup

Twitter lit up Friday after one of Derek Lowe's posts on his In the Pipeline blog elicited an anonymous but very specific comment on changes being made in R&D now that Roger Perlmutter has taken over the research division.

Icahn ally added to Forest board

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Top AstraZeneca exec bows out to helm a biotech

AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin American division raised a few eyebrows around the industry.

Forest, Icahn playing nice this time around

In a stark turnabout from last year, Forest Laboratories and cantankerous investor Carl Icahn are making nice ahead of the company's annual shareholder meeting.

Forest prepares to negotiate with investor Icahn on board positions

Forest Laboratories faces another proxy battle as its annual investor meeting this summer looms. Icahn, the company's second largest shareholder, has been highly critical of the company's leadership.

Forrester is Verastem CEO after Westphal steps down

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...